Skip to content
Vorinostat
Zolinza (vorinostat) is a small molecule pharmaceutical. Vorinostat was first approved as Zolinza on 2006-10-06. It is used to treat t-cell lymphoma cutaneous in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 2, histone deacetylase 11, histone deacetylase 9, histone deacetylase 5, histone deacetylase 8, histone deacetylase 3, polyamine deacetylase HDAC10, and histone deacetylase 6.
Download report
Favorite
SARS-CoV-2 Interaction
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Zolinza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vorinostat
Tradename
Company
Number
Date
Products
ZOLINZAMerck Sharp & DohmeN-021991 RX2006-10-06
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zolinzaNew Drug Application2020-01-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
t-cell lymphoma cutaneous—D016410C84.A
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Vorinostat, Zolinza, Msd Sub Merck
84503722028-03-18U-892
74562192027-03-11DP
80932952026-05-16DP
73997872025-02-09U-892
78515092024-02-21DPU-892
76520692023-03-04DP
77324902023-03-04U-892
80674722023-03-04U-892
81016632023-03-04U-892
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XH: Histone deacetylase (hdac) inhibitors
— L01XH01: Vorinostat
HCPCS
No data
Clinical
Clinical Trials
268 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.017111——26
LymphomaD008223C85.917101——22
Non-small-cell lung carcinomaD00228916101——21
Multiple myelomaD009101C90.01392——20
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01571——19
AstrocytomaD001254EFO_0000271521——6
T-cell lymphoma cutaneousD016410C84.A141—16
Lung neoplasmsD008175C34.90211—14
Spinal cord neoplasmsD013120EFO_0003828C72.0111——2
MesotheliomaD008654C45——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80284———30
Breast neoplasmsD001943EFO_0003869C501113——322
Myelodysplastic syndromesD009190D461210———19
Non-hodgkin lymphomaD008228C85.9128———18
Mantle-cell lymphomaD020522C83.178———13
Follicular lymphomaD008224C8287———12
Large b-cell lymphoma diffuseD016403C83.396———12
GlioblastomaD005909EFO_000051587——112
Hodgkin diseaseD006689C8194———11
NeuroblastomaD009447EFO_000062163——110
Show 86 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MedulloblastomaD0085274————4
OligodendrogliomaD009837EFO_00006314————4
Germ cell and embryonal neoplasmsD0093733————3
Plasma cell neoplasmsD0542193————3
Esophageal neoplasmsD004938C152———13
Adult t-cell leukemia-lymphomaD015459C91.53————3
Primary myelofibrosisD055728D47.42————2
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.22————2
Myelomonocytic leukemia juvenileD054429C93.32————2
TeratomaD013724D282————2
Show 33 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863F33.9————11
Triple negative breast neoplasmsD064726————11
Head and neck neoplasmsD006258————11
PheochromocytomaD010673————11
ParagangliomaD010235————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVORINOSTAT
INNvorinostat
Description
Vorinostat is a dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a hydroxamic acid and a dicarboxylic acid diamide. It is functionally related to a suberic acid, a hydroxylamine and an aniline.
Classification
Small molecule
Drug classenzyme inhibitors: histone deacetylase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(CCCCCCC(=O)Nc1ccccc1)NO
Identifiers
PDB4BZ6
CAS-ID149647-78-9
RxCUI194337
ChEMBL IDCHEMBL98
ChEBI ID45716
PubChem CID5311
DrugBankDB02546
UNII ID58IFB293JI (ChemIDplus, GSRS)
Target
Agency Approved
HDAC1
HDAC1
Organism
Homo sapiens
Gene name
HDAC1
Gene synonyms
RPD3L1
NCBI Gene ID
3065
Protein name
histone deacetylase 1
Protein synonyms
Protein deacetylase HDAC1, Protein decrotonylase HDAC1, reduced potassium dependency, yeast homolog-like 1
Uniprot ID
Q92534
Mouse ortholog
Hdac1 (433759)
histone deacetylase 1 (P97476)
Alternate
HDAC2
HDAC2
HDAC11
HDAC11
HDAC9
HDAC9
HDAC5
HDAC5
HDAC8
HDAC8
HDAC3
HDAC3
HDAC10
HDAC10
HDAC6
HDAC6
Organism
Homo sapiens
Gene name
HDAC2
Gene synonyms
NCBI Gene ID
3066
Protein name
histone deacetylase 2
Protein synonyms
Protein deacylase HDAC2, transcriptional regulator homolog RPD3, YY1-associated factor 1
Uniprot ID
Q92769
Mouse ortholog
Hdac2 (15182)
histone deacetylase 2 (P70288)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,269 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,039 adverse events reported
View more details